duchenn
muscular
dystrophi
dmd
sever
muscl
degen
disord
character
mutat
disrupt
read
frame
dystrophin
dmd
gene
lead
absenc
function
protein
relat
allel
disord
becker
muscular
dystrophi
bmd
caus
mutat
give
rise
shorten
infram
transcript
result
product
truncat
partial
function
protein
partial
function
protein
retain
critic
amino
termin
cystein
rich
ctermin
domain
usual
lack
element
central
rod
domain
less
function
signific
consequ
bmd
phenotyp
rang
mild
dmd
virtual
asymptomat
depend
precis
mutat
level
dystrophin
produc
antisens
oligonucleotid
ao
mediat
splice
modif
outoffram
dystrophin
transcript
demonstr
exclud
specif
dystrophin
exon
therebi
restor
open
read
frame
result
product
beckerlik
shorten
partial
function
dystrophin
protein
util
modifi
oligonucleotid
deliv
direct
intramuscular
inject
lu
et
al
demonstr
molecular
correct
dystrophin
transcript
mdx
mice
bear
nonsens
mutat
exon
result
local
dystrophin
product
function
improv
proofofprincipl
therapeut
approach
also
success
shown
human
subject
use
similar
local
intramuscular
aoinject
protocol
develop
aomedi
exonskip
effect
therapi
dmd
requir
system
correct
molecular
defect
includ
cardiac
muscl
given
cardiomyopathi
signific
caus
morbid
death
dmd
patient
restor
dystrophin
express
heart
critic
requir
success
exon
skip
therapi
previou
work
shown
altern
chemistri
phosphorodiamid
morpholino
oligom
pmo
capabl
restor
dystrophin
express
multipl
muscl
group
follow
system
intraven
deliveri
mdx
mice
requir
highdos
multiinject
protocol
molecular
correct
cardiac
muscl
observ
short
posit
charg
argininerich
peptid
shown
function
cell
penetr
peptid
enhanc
cell
uptak
varieti
cargo
includ
oligonucleotid
conjug
previous
demonstr
effect
splice
correct
mutant
dystrophin
transcript
cell
cultur
also
neonat
mdx
mice
via
intraperiton
inject
demonstr
potenti
enhanc
deliveri
exonskip
efficaci
ao
evalu
two
argininerich
peptidepmo
conjug
adult
mdx
mice
system
intraven
inject
demonstr
highli
effect
widespread
dystrophin
correct
multipl
peripher
skelet
muscl
cardiac
muscl
low
system
ao
dose
given
highlevel
intramuscular
correct
obtain
two
pmopeptid
conjug
therefor
investig
whether
singl
intraven
inject
pmo
conjug
could
restor
dystrophin
express
system
mgkg
singl
inject
administr
protocol
test
conjug
administ
via
mous
tail
vein
three
week
follow
singl
inject
skelet
muscl
fibr
immunostain
posit
sarcolemm
dystrophin
intens
dystrophin
express
near
normal
skelet
muscl
group
analys
although
slightli
lower
bicep
shown
fig
widespread
uniform
express
dystrophin
protein
multipl
tissu
section
within
muscl
group
detect
hind
limb
fore
limb
abdomin
wall
diaphragm
muscl
surprisingli
obviou
areato
area
variat
found
within
individu
muscl
group
previous
report
system
deliveri
nake
pmo
ao
rtpcr
result
reveal
almost
total
exon
skip
mutat
transcript
highli
effect
skip
mdx
dystrophin
exon
fig
skelet
muscl
analys
includ
diaphragm
less
effici
molecular
correct
observ
heart
mutat
transcript
found
exon
skip
rtpcr
shorter
band
also
detect
rtpcr
assay
mani
analys
tissu
like
correspond
skip
transcript
lack
exon
subsequ
sequenc
pcr
fragment
confirm
minor
transcript
product
contain
exon
delet
data
shown
quantifi
level
dystrophin
protein
restor
western
blot
analysi
undertaken
use
total
protein
extract
muscl
group
includ
heart
normal
ta
heart
muscl
tissu
posit
control
indic
normal
dystrophin
protein
level
restor
bodywid
skelet
muscl
follow
singl
system
ao
inject
particular
signific
level
approach
restor
dystrophin
protein
detect
distal
muscl
group
ie
ta
bicep
even
diaphragm
almost
normal
dystrophin
protein
restor
fig
cardiac
tissu
treat
mice
also
analys
immunostain
demonstr
wide
distribut
dystrophinposit
fibr
throughout
cardiac
muscl
fig
dystrophin
protein
restor
found
high
heart
peripher
skelet
muscl
group
level
found
normal
mous
heart
typic
seen
western
analysi
treat
anim
fig
first
demonstr
widespread
dystrophin
protein
correct
mdx
mous
heart
low
ao
dose
contain
altern
arginin
nonnatur
aminohexano
acid
amino
acid
rxr
sequenc
test
efficaci
modifi
argininerich
pmopeptid
conjug
directli
compar
second
conjug
bpmo
contain
transduct
peptid
two
aminohexano
acid
residu
substitut
residu
second
nonnatur
amino
acid
see
peptid
sequenc
tabl
take
approach
bpmo
deliv
intraven
deliveri
also
demonstr
highli
effect
system
dystrophin
correct
skelet
muscl
cardiac
tissu
lower
effici
ao
dose
shown
western
analysi
supplementari
materi
fig
rtpcr
data
show
almost
complet
exon
skip
rna
level
major
skelet
muscl
follow
treatment
mgkg
ao
dose
suggest
possibl
ao
dose
reach
near
satur
tissu
given
find
halflif
dystrophin
protein
vivo
estim
week
mdx
mice
decid
test
whether
modif
ao
deliveri
protocol
includ
multipl
lowerdos
inject
could
improv
molecular
dystrophin
correct
without
ao
dose
satur
skelet
muscl
protocol
weekli
inject
mgkg
week
result
lower
total
ao
dose
administ
significantli
improv
molecular
correct
compar
agematch
control
bodywid
muscl
shown
immunostain
fig
high
level
dystrophin
express
detect
ta
quadricep
gastrocnemiu
muscl
compar
found
follow
mgkg
dose
strike
differ
seen
abdomin
wall
muscl
diaphragm
heart
lower
level
dystrophin
correct
found
mgkg
dose
regim
compar
mgkg
dose
rtpcr
result
consist
immunostain
data
show
almost
complet
exon
skip
ta
quadricep
gastrocnemiu
muscl
exon
skip
effici
diaphragm
abdomin
wall
muscl
even
less
dystrophin
exon
skip
detect
heart
although
dystrophinposit
fibr
observ
cardiac
tissu
immunostain
fig
western
blot
data
demonstr
lower
level
protein
restor
abdomin
wall
diaphragm
heart
tissu
compar
seen
follow
mgkg
treatment
consist
rtpcr
immunostain
find
fig
lowerdos
studi
also
compar
second
peptidepmo
approach
result
confirm
compound
superior
activ
bpmo
determin
rna
data
shown
protein
level
supplementari
materi
fig
dystrophin
play
critic
role
muscl
link
cytoplasm
actin
sarcolemm
dystrophinassoci
protein
complex
dapc
via
extracellular
matrix
dapc
also
import
signal
function
via
nno
compon
absenc
function
dystrophin
dapc
fail
local
accur
sarcolemma
function
compromis
therefor
investig
whether
restor
dystrophin
protein
express
via
system
deliveri
result
success
reloc
dapc
protein
constitu
sarcolemma
expect
express
multipl
dapc
compon
protein
includ
nno
detect
peripher
skelet
muscl
correct
sarcolemm
local
stain
intens
commensur
observ
dystrophin
mgkg
dose
fig
restor
dapc
compon
also
observ
mgkg
dose
studi
although
correspondingli
lower
level
express
data
shown
result
success
restor
dystrophin
dapc
express
wish
determin
whether
evid
improv
muscl
function
could
detect
use
function
test
grip
forc
strength
evalu
predominantli
exclus
forelimb
muscl
strength
mdx
mice
treat
ao
shown
significantli
improv
grip
strength
within
normal
rang
follow
mgkg
dose
compar
untreat
mdx
control
mice
fig
improv
also
detect
mdx
mice
treat
mgkg
dose
great
seen
follow
mgkg
treatment
data
shown
percentag
muscl
fibr
central
locat
nuclei
index
ongo
degenerationregener
cycl
count
central
locat
nuclei
within
treat
mdx
muscl
group
ta
gastrocnemiu
quadricep
reveal
signific
reduct
central
nucleat
myofibr
compar
untreat
control
mdx
mice
suggest
reduc
regen
stimulu
restor
normal
myofibr
architectur
commensur
improv
function
fig
also
signific
fall
number
central
nucleat
fibr
ta
gastrocnemiu
muscl
mgkg
dose
data
shown
serum
creatin
kinas
ck
level
elev
mdx
mice
indic
ongo
muscl
patholog
membran
instabl
significantli
lower
level
serum
ck
found
treat
mdx
mice
compar
untreat
control
indic
widespread
protect
effect
restor
dystrophin
express
myofibr
integr
fig
mdx
mice
treat
peptidepmo
conjug
demonstr
obviou
outward
sign
ill
health
order
monitor
potenti
system
cytotox
induc
pmo
andor
conjug
peptid
undertook
histolog
studi
liver
kidney
tissu
analys
seri
serum
marker
commonli
use
indic
liver
kidney
dysfunct
haematoxylin
eosin
stain
liver
kidney
tissu
section
reveal
overt
sign
tissu
damag
mdx
mice
treat
conjug
deleteri
chang
detect
tissu
morpholog
increas
number
infiltr
cell
compar
untreat
mdx
control
mice
particular
interest
liver
histolog
evid
toxic
found
follow
treatment
revers
typic
swollen
hepat
cell
patholog
found
untreat
mdx
mice
seen
fig
serum
collect
treat
mdx
mice
control
mice
show
signific
decreas
level
aspart
aminotransferas
ast
alanin
aminotransferas
alt
liver
enzym
treat
mice
level
enzym
return
within
normal
rang
compar
untreat
mdx
mice
normal
agematch
untreat
control
mice
fig
chang
found
serum
level
urea
creatinin
treatment
compar
untreat
mdx
control
normal
mice
data
shown
suggest
advers
effect
treatment
renal
function
dose
studi
overal
result
indic
cours
experi
conjug
induc
overt
hepat
renal
toxic
system
dose
mgkg
mdx
mice
sign
toxic
observ
mgkg
dose
regim
data
shown
report
demonstr
effect
system
dystrophin
correct
adult
mdx
dystroph
mice
peripher
skelet
muscl
cardiac
tissu
use
pmo
ao
conjug
argininerich
peptid
administ
low
system
dose
singl
mgkg
intraven
dose
pmopeptid
conjug
suffici
rescu
high
level
sarcolemm
dystrophin
protein
dapc
compon
reloc
histolog
function
correct
conjug
demonstr
greater
efficaci
highlight
potenti
pmopeptid
conjug
compound
therapeut
valu
bodywid
cardiac
dystrophin
correct
corrobor
recent
report
relat
conjug
clinic
studi
evalu
ao
exon
skip
dmd
patient
progress
netherland
uk
use
phosphorothio
pmo
ao
compound
respect
aopeptid
conjug
therefor
offer
possibl
effici
system
cardiac
dystrophin
correct
significantli
lower
dose
previous
use
unconjug
ao
mdx
mice
reduc
possibl
concern
regard
potenti
toxic
high
dose
phosphorothio
pmo
ao
human
subject
cost
ao
studi
warrant
fulli
investig
toxicolog
profil
transduct
peptid
use
report
found
evid
system
toxic
treat
mdx
mice
cours
experi
previou
work
investig
pmobas
exon
skip
adult
mdx
mice
fail
find
evid
cardiac
dystrophin
correct
even
high
multipl
dose
mgkg
data
demonstr
widespread
dystrophin
correct
heart
protein
level
restor
normal
week
follow
singl
intraven
ao
inject
show
intrins
barrier
cardiac
dystrophin
correct
mdx
mice
use
ao
therapeut
agent
inde
high
effici
aomedi
exon
skip
achiev
primari
mdx
cardiomyocyt
walker
wood
yin
unpublish
data
given
correct
cardiac
defect
due
loss
dystrophin
protein
essenti
compon
success
dmd
therapi
therapi
restor
dystrophin
skelet
muscl
cardiac
muscl
may
exacerb
underli
cardiac
patholog
pmopeptid
conjug
signific
potenti
system
correct
dmd
phenotyp
mechan
argininerich
rxr
transduct
peptid
facilit
cardiac
ao
deliveri
efficaci
within
tissu
remain
unclear
cation
peptid
thought
bind
cellassoci
glycosaminoglycan
subsequ
intern
endocytosi
thu
mechan
biochem
event
may
lead
enhanc
transvascular
ao
deliveri
cardiac
muscl
tissu
understood
nevertheless
highli
effici
cardiac
muscl
gene
deliveri
achiev
use
aav
vector
includ
deliveri
splice
correct
dna
construct
therefor
seem
plausibl
argininerich
transduct
peptid
permit
effici
transvascular
ao
tissu
entri
tissu
via
similar
mechan
readministr
peptid
pmo
ao
requir
data
suggest
similar
level
cardiac
dystrophin
correct
may
achiev
compar
found
use
aav
antisens
strategi
without
potenti
disadvantag
toxic
immunolog
effect
attribut
vector
mechanist
insight
structureact
studi
like
identifi
improv
peptid
transvascular
cardiac
ao
transduct
whether
restor
cardiac
dystrophin
protein
normal
level
like
adequ
regain
maintain
normal
cardiac
function
unknown
studi
requir
particularli
dmd
anim
model
manifest
signific
cardiac
phenotyp
eg
dystrophin
utrophin
defici
dko
mice
golden
retriev
dog
model
howev
dmd
patient
degre
cardiac
function
regain
maintain
depend
level
dystrophin
protein
restor
also
particular
bmdlike
dystrophin
isoform
restor
exon
skip
case
given
bmd
cardiac
phenotyp
highli
heterogen
data
show
widespread
uniform
highlevel
dystrophin
protein
express
mdx
peripher
muscl
group
studi
includ
central
abdomin
wall
diaphragm
muscl
week
follow
treatment
singl
mgkg
pmopeptid
dose
mani
muscl
group
demonstr
dystrophin
protein
restor
level
excess
normal
significantli
higher
report
previous
use
nake
pmo
compound
estim
first
human
clinic
studi
direct
intramuscular
deliveri
phosphorothio
ao
consequ
found
dapc
protein
compon
effici
reloc
muscl
histolog
appear
normal
muscl
grip
strength
restor
within
normal
rang
rtpcr
analysi
use
nest
reaction
cycl
reveal
tissu
except
heart
virtual
mutant
transcript
success
skip
suggest
possibl
aotarget
satur
therefor
test
whether
lower
dose
pmopeptid
conjug
could
effect
restor
dystrophin
express
near
normal
level
dystrophin
protein
restor
peripher
muscl
lower
dose
central
muscl
includ
diaphragm
heart
less
well
correct
dystrophin
dapc
protein
level
question
therefor
aris
optim
dose
regim
pmopeptid
ao
given
data
high
mgkg
dose
estim
halflif
dystrophin
protein
approach
week
mdx
mice
peptid
conjug
known
increas
pmo
tissu
uptak
retent
singl
higher
pmopeptid
threshold
dose
follow
lower
mainten
dose
week
interv
may
optim
studi
requir
determin
evalu
longerterm
function
physiolog
effect
treatment
sixtoeightweek
old
mdx
mice
use
experi
six
mice
test
four
control
group
experi
carri
anim
unit
depart
physiolog
anatomi
genet
univers
oxford
oxford
uk
accord
procedur
author
uk
home
offic
mice
kill
inhal
cervic
disloc
desir
time
point
muscl
tissu
snapfrozen
liquid
nitrogencool
isopentan
store
detail
pmo
pmopeptid
conjug
shown
tabl
conjug
peptid
pmo
synthes
stabl
amid
linker
describ
elsewher
conjug
synthes
avi
biopharma
inc
corval
usa
pmo
ao
sequenc
boundari
sequenc
exon
intron
dystrophin
gene
design
pmo
total
rna
extract
skelet
muscl
heart
tissu
trizol
invitrogen
uk
ng
rna
templat
use
rtpcr
onestep
rtpcr
kit
qiagen
uk
primer
sequenc
initi
rtpcr
amplif
messeng
rna
exon
cycl
condit
min
min
cycl
rtpcr
product
use
templat
secondari
pcr
perform
taq
dna
polymeras
invitrogen
uk
primer
sequenc
second
round
cycl
condit
min
min
min
cycl
product
examin
electrophoresi
agaros
gel
intramuscular
studi
ta
muscl
experiment
mdx
mous
inject
dose
conjug
salin
final
concentr
contralater
muscl
inject
salin
system
intraven
inject
pmopeptid
conjug
salin
buffer
inject
tail
vein
mdx
mice
final
dose
mgkg
mgkg
respect
anim
kill
variou
time
point
inject
inhal
tissu
remov
snapfrozen
liquid
nitrogencool
isopentan
store
section
cut
least
twothird
muscl
length
ta
quadricep
gastrocnemiu
bicep
abdomin
wall
diaphragm
muscl
cardiac
muscl
interv
section
examin
dystrophin
express
polyclon
antibodi
dystrophin
ctermin
region
antibodi
kindli
provid
professor
kay
davi
maximum
number
dystrophinposit
fibr
one
section
count
use
zeiss
axiovis
fluoresc
microscop
interven
muscl
section
collect
either
rtpcr
analysi
western
blot
serial
section
immunohistochemistri
polyclon
antibodi
detect
goatantirabbit
igg
alexa
fluro
molecular
probe
uk
routin
haematoxylin
eosin
stain
use
examin
overal
muscl
morpholog
assess
level
infiltr
mononuclear
cell
serial
section
also
stain
panel
polyclon
monoclon
antibodi
detect
dapc
protein
compon
rabbit
polyclon
antibodi
neuron
nitric
oxid
synthas
nno
mous
monoclon
antibodi
dystroglycan
use
accord
manufactur
instruct
novocastra
uk
polyclon
antibodi
detect
goatantirabbit
igg
alexa
monoclon
antibodi
goatantimous
igg
alexa
molecular
probe
uk
mom
block
kit
vector
laboratori
inc
burlingam
ca
appli
immunostain
dapc
ta
quadricep
gastrocnemiu
muscl
mdx
mice
treat
pmopeptid
conjug
examin
ascertain
number
central
nucleat
muscl
fibr
section
stain
dystrophin
rabbit
polyclon
antibodi
counterstain
dapi
cell
nuclei
sigma
uk
dystrophin
posit
fibr
tissu
sampl
count
assess
presenc
central
nuclei
use
zeiss
axiovis
fluoresc
microscop
fibr
judg
central
nucleat
one
nuclei
locat
peripheri
fibr
untreat
agematch
mdx
mice
use
control
collect
section
place
ml
polypropylen
eppendorf
tube
anachem
uk
dri
ice
tissu
section
lyse
protein
extract
buffer
contain
mmoll
ph
sodium
dodecyl
sulphat
moll
urea
glycerol
mixtur
boil
min
centrifug
supernat
collect
protein
concentr
quantifi
bradford
assay
sigma
uk
variou
amount
protein
normal
mice
posit
control
correspond
amount
protein
muscl
treat
untreat
mdx
mice
load
onto
sodium
dodecyl
sulphat
polyacrylamid
gel
electrophoresi
gel
stack
resolv
sampl
electrophores
h
transfer
nitrocellulos
overnight
v
membran
wash
block
skim
milk
probe
overnight
monoclon
antibodi
dystrophin
repeat
novocastra
uk
detect
dytstrophin
protein
monoclon
antibodi
sigma
uk
load
control
bound
primari
antibodi
detect
horseradish
peroxidiseconjug
rabbit
antimous
igg
ecl
western
blot
analysi
system
amersham
pharmacia
bioscienc
uk
intens
band
obtain
treat
mdx
muscl
measur
imag
j
softwar
quantif
base
band
intens
area
compar
normal
muscl
mice
treat
mice
control
mice
test
use
commerci
grip
strength
monitor
chatillon
uk
mous
held
cm
base
tail
allow
grip
protrud
metal
triangl
bar
attach
apparatu
forepaw
pull
gentli
releas
grip
forc
exert
record
five
sequenti
test
carri
mous
averag
apart
serum
plasma
taken
mous
jugular
vein
immedi
kill
inhal
analysi
serum
ck
ast
alt
urea
creatinin
level
perform
clinic
patholog
laboratori
mari
lyon
centr
medic
research
council
harwel
oxfordshir
uk
data
report
mean
valu
sem
statist
differ
treatment
group
control
group
evalu
sigmastat
systat
softwar
uk
onetail
ttest
appli
supplementari
materi
avail
hmg
onlin
work
support
uk
depart
health
uk
muscular
dystrophi
campaign
